Afferent Pharmaceuticals

Merck & Co., Inc. is facing another setback in its efforts to diversify its revenue stream outside of Keytruda (pembrolizumab) with a complete response letter for its P2X3 receptor antagonist gefapix

The first weeks of March brought in a flurry of new drug applications to the US Food and Drug Administration, including two new molecular entities from big pharma stalwart Merck & Co., Inc. . Towards

Merck & Co. Inc. has presented promising late-stage data on gefapixant which the US giant hopes will become the first approved therapy for chronic cough. Touted by Merck as one of the key drugs in it

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biophar